Bulevirtide Improves Health-Related Quality of Life Measured by EQ-5D VAS in Patients With Chronic Hepatitis Delta: An Exploratory Analysis of a Phase 3 Trial at 48 Weeks

Conference Reports for NATAP

The Liver Meeting
Digital Experience
AASLD
Washington on 04-08
November 2022


Bulevirtide Improves Health-Related Quality of Life Measured by EQ-5D VAS in Patients With Chronic Hepatitis Delta: An Exploratory Analysis of a Phase 3 Trial at 48 Weeks

	AASLD nov 4-8 2022